Skeletal Muscle Manifestations and Creatine Kinase in COVID-19.
CK
COVID-19
Creatine Phosphokinase
SARS-CoV-2
coronavirus
creatine kinase
myalgia
myopathy
Journal
The Neurohospitalist
ISSN: 1941-8744
Titre abrégé: Neurohospitalist
Pays: United States
ID NLM: 101558199
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
entrez:
23
9
2022
pubmed:
24
9
2022
medline:
24
9
2022
Statut:
ppublish
Résumé
Skeletal muscle symptoms and elevated creatine kinase (CK) levels have been consistently reported as part of the COVID-19 disease process. Previous studies have yet to show a consistent relationship between CK levels and skeletal muscle symptoms, disease severity, and death from COVID-19. The purpose of this study is to determine whether elevated CK is associated with a COVID-19 course requiring intubation, intensive care, and/or causing death. Secondary objectives: To determine if there is a relationship between elevated CK and (1) skeletal muscle symptoms/signs (2) complications of COVID-19 and (3) other diagnostic laboratory values. This is a retrospective, single center cohort study. Data were collected from March 13, 2020, to May 13, 2020. This study included 289 hospitalized patients with laboratory-confirmed SARS-CoV-2 and measured CK levels during admission. Of 289 patients (mean age 68.5 [SD 13.8] years, 145 [50.2%] were men, 262 [90.7%] were African American) with COVID-19, 52 (18.0%) reported myalgia, 92 (31.8%) reported subjective weakness, and 132 (45.7%) had elevated CK levels (defined as greater than 220 U/L). Elevated CK was found to be associated with severity of disease, even when adjusting for inflammatory marker C-reactive protein (initial CK: OR 1.006 [95% CI: 1.002-1.011]; peak CK: OR 1.006 [95% CI: 1.002-1.01]; last CK: 1.009 [95% CI: 1.002-1.016]; q = .04). Creatine kinase was not found to be associated with skeletal muscle symptoms/signs or with other laboratory markers. Creatine kinase is of possible clinical significance and may be used as an additional data point in predicting the trajectory of the COVID-19 disease process.
Sections du résumé
Background and Purpose
UNASSIGNED
Skeletal muscle symptoms and elevated creatine kinase (CK) levels have been consistently reported as part of the COVID-19 disease process. Previous studies have yet to show a consistent relationship between CK levels and skeletal muscle symptoms, disease severity, and death from COVID-19. The purpose of this study is to determine whether elevated CK is associated with a COVID-19 course requiring intubation, intensive care, and/or causing death. Secondary objectives: To determine if there is a relationship between elevated CK and (1) skeletal muscle symptoms/signs (2) complications of COVID-19 and (3) other diagnostic laboratory values.
Methods
UNASSIGNED
This is a retrospective, single center cohort study. Data were collected from March 13, 2020, to May 13, 2020. This study included 289 hospitalized patients with laboratory-confirmed SARS-CoV-2 and measured CK levels during admission.
Results
UNASSIGNED
Of 289 patients (mean age 68.5 [SD 13.8] years, 145 [50.2%] were men, 262 [90.7%] were African American) with COVID-19, 52 (18.0%) reported myalgia, 92 (31.8%) reported subjective weakness, and 132 (45.7%) had elevated CK levels (defined as greater than 220 U/L). Elevated CK was found to be associated with severity of disease, even when adjusting for inflammatory marker C-reactive protein (initial CK: OR 1.006 [95% CI: 1.002-1.011]; peak CK: OR 1.006 [95% CI: 1.002-1.01]; last CK: 1.009 [95% CI: 1.002-1.016]; q = .04). Creatine kinase was not found to be associated with skeletal muscle symptoms/signs or with other laboratory markers.
Conclusions
UNASSIGNED
Creatine kinase is of possible clinical significance and may be used as an additional data point in predicting the trajectory of the COVID-19 disease process.
Identifiants
pubmed: 36147765
doi: 10.1177/19418744221105961
pii: 10.1177_19418744221105961
pmc: PMC9160579
doi:
Types de publication
Journal Article
Langues
eng
Pagination
597-606Informations de copyright
© The Author(s) 2022.
Déclaration de conflit d'intérêts
Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
Clin Microbiol Infect. 2020 Jun;26(6):767-772
pubmed: 32304745
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
J Appl Physiol (1985). 2020 Oct 1;129(4):864-867
pubmed: 32673162
Noro Psikiyatr Ars. 2020 May 01;57(2):154-159
pubmed: 32550783
Muscle Nerve. 2020 Sep;62(3):E57-E60
pubmed: 32535934
Crit Rev Clin Lab Sci. 1981;15(3):187-230
pubmed: 7032842
Eur J Intern Med. 2020 Jun;76:97-99
pubmed: 32345526
Arthritis Rheum. 2009 Dec;60(12):3755-60
pubmed: 19950271
J Infect Dis. 2005 Jan 15;191(2):193-7
pubmed: 15609228
Am J Emerg Med. 2020 Jul;38(7):1548.e1-1548.e3
pubmed: 32414522
J Neurol Neurosurg Psychiatry. 1966 Aug;29(4):331-7
pubmed: 5229994
J Med Virol. 2020 Nov;92(11):2616-2622
pubmed: 32470186
Clin Chem Lab Med. 2020 Jun 25;58(7):1100-1105
pubmed: 32573995
Neurology. 2020 Jun 2;94(22):959-969
pubmed: 32284362
Continuum (Minneap Minn). 2019 Dec;25(6):1712-1731
pubmed: 31794468
Genes Immun. 2012 Apr;13(3):207-13
pubmed: 21881594
Neurol Sci. 2020 Aug;41(8):1991-1995
pubmed: 32588367
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Neurol Sci. 2020 Aug;41(8):2029-2031
pubmed: 32617738
Am J Respir Crit Care Med. 2020 Jun 1;201(11):1380-1388
pubmed: 32275452
Eur J Med Res. 2020 Aug 3;25(1):30
pubmed: 32746929
J Clin Med. 2021 Apr 16;10(8):
pubmed: 33923719
J Med Virol. 2021 Feb;93(2):1078-1098
pubmed: 32776551
Pediatr Nephrol. 2020 Aug;35(8):1517-1520
pubmed: 32447505
Emerg Infect Dis. 2004 May;10(5):818-24
pubmed: 15200814
Arch Neurol. 2004 Nov;61(11):1669-73
pubmed: 15534177
BMJ Case Rep. 2020 Sep 2;13(9):
pubmed: 32878841
Neurology. 2021 Aug 24;97(8):e849-e858
pubmed: 34099523
Neurology. 2020 Aug 25;95(8):e1060-e1070
pubmed: 32482845
N Engl J Med. 2020 Dec 10;383(24):2389-2390
pubmed: 33216474
Am J Med. 2009 Jan;122(1):73-8
pubmed: 19114174
BMJ. 2020 Mar 26;368:m1091
pubmed: 32217556
JAMA. 2020 May 19;323(19):1891-1892
pubmed: 32293639
Clin Chem Lab Med. 2020 Jun 25;58(7):1021-1028
pubmed: 32286245
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Br J Anaesth. 2020 Sep;125(3):e334-e336
pubmed: 32600801
J Microbiol Immunol Infect. 2006 Feb;39(1):45-53
pubmed: 16440123
Neurologia (Engl Ed). 2020 Nov - Dec;35(9):621-627
pubmed: 32912745
J Med Virol. 2020 Jun;92(6):577-583
pubmed: 32162702
Nat Rev Immunol. 2020 Oct;20(10):585-586
pubmed: 32788708
Int J Infect Dis. 2020 May;94:91-95
pubmed: 32173574
Eur J Neurol. 2021 Oct;28(10):3411-3417
pubmed: 32997370
Nat Commun. 2020 Jul 30;11(1):3810
pubmed: 32733001
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
J Clin Lab Anal. 2020 Oct;34(10):e23467
pubmed: 32656888
Am J Med Sci. 2020 Jul;360(1):5-34
pubmed: 32620220
Ann Rheum Dis. 2021 Mar;80(3):e42
pubmed: 32327427
Acta Neurol Taiwan. 2005 Sep;14(3):113-9
pubmed: 16252612
Emerg Infect Dis. 2020 Jul;26(7):1618-1620
pubmed: 32197060
Rheumatol Int. 2020 Nov;40(11):1741-1751
pubmed: 32880032
JAMA Neurol. 2020 Jun 1;77(6):683-690
pubmed: 32275288
Biomark Res. 2020 Aug 31;8:37
pubmed: 32879731
Cureus. 2020 May 12;12(5):e8074
pubmed: 32542129